预约演示
更新于：2026-07-16
Regadenoson
瑞加诺生
更新于：2026-07-16
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H20N8O6 |
InChIKeyCDQVVPUXSPZONN-WPPLYIOHSA-N |
CAS号875148-45-1 |
关联
78
项与 瑞加诺生 相关的临床试验NCT05583721
An Evaluation of the Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET (Stress-Rest) Myocardial Perfusion Imaging (MYPERS)
CTR20231854
瑞加诺生注射液用于负荷超声心动图试验诊断冠心病的多中心、随机、自身对照、阳性药对照的Ⅲ期临床研究
CTIS2024-519979-26-00
Evaluation of patients with total coronary occlusions with multimodality image.
100 项与 瑞加诺生 相关的临床结果
登录后查看更多信息
100 项与 瑞加诺生 相关的转化医学
登录后查看更多信息
100 项与 瑞加诺生 相关的专利（医药）
登录后查看更多信息
468
项与 瑞加诺生 相关的文献（医药）2026-05-01Diagnostic and Interventional Imaging
Using regadenoson for stress first-pass perfusion cardiac MR imaging: How, when, and why?
Review
作者: Dacher, Jean-Nicolas ; Chennoufi, Hajer ; Mulot, Bon-Marin ; Demeyere, Matthieu ; Boccalini, Sara
Cardiac magnetic resonance imaging (MRI) is a valuable tool for ruling out coronary artery disease, assessing cardiac viability, diagnosing myocardial ischemia, and providing prognostic information. Cardiac MRI, including vasodilator-induced first-pass perfusion imaging, is recommended for patients with a high probability of coronary disease, prior to revascularization, and when a viability assessment is necessary. Adenosine is the most commonly used vasodilating agent for stress cardiac MRI worldwide. However, regadenoson, which is an adenosine A2A receptor agonist, is a highly suitable alternative for stress cardiac MRI due to its kinetic properties, ease of use, single-dose administration, limited contraindications, and prognostic value. This technical note describes the characteristics and safety profile of regadenoson and discusses its application to cardiac MRI and reimbursement issues.
2026-05-01JOURNAL OF NUCLEAR CARDIOLOGY
Blunted heart rate response to regadenoson predicts cardiovascular risk beyond quantitative positron emission tomography myocardial blood flow
Article
作者: Stendahl, John C ; Gallegos Kattan, Cesia ; Barreto, Joaquim ; Sinusas, Albert ; Feher, Attila ; Sadeghi, Mehran M ; Vashist, Aseem ; Miller, Edward J ; Moura, Filipe A ; Sposito, Andrei C
OBJECTIVE:
To evaluate the incremental prognostic value of a blunted heart rate response (HRR) to regadenoson beyond PET-derived myocardial flow parameters.
BACKGROUND:
A blunted HRR during pharmacologic stress with regadenoson, an adenosine A2A receptor agonist, may reflect autonomic dysfunction and heightened cardiovascular (CV) risk. Whether HRR provides prognostic information beyond stress myocardial blood flow (sMBF) and myocardial flow reserve (MFR) remains uncertain.
METHODS:
We retrospectively analyzed consecutive rest-stress 82Rb PET/CT studies performed between 2016 and 2022. Abnormal sMBF and MFR were defined as less than 1.8 mL/min/g and <2.0, respectively. HRR was calculated as (peak HR - rest HR)/rest HR and considered blunted if less than 20%. We compared differences in major adverse cardiovascular events (MACE: death, myocardial infarction, stroke, or heart failure hospitalization) between patients with blunted and normal HRR using multivariable Cox regression, stratified by sMBF and MFR. Nonlinear associations between HRR and MACE were evaluated using restricted cubic splines. Incremental prognostic value was assessed by changes in the area under the receiver-operating characteristic curve (AUC) and net reclassification index (NRI).
RESULTS:
Among 4611 patients (63 ± 11 years; 54% female), 1263 (27%) had blunted HRR. These patients had a higher prevalence of abnormal sMBF (49% vs 27%) and MFR (66% vs 30%). Over a median follow-up of 3.3 years (IQR 1.8-5.1), MACE rates were higher among patients with blunted HRR (16.2 vs 5.5 events/100 patient-years; adjusted HR 1.70 [95% CI: 1.50-1.94]; P < .001), irrespective of sMBF or MFR status. Risk increased progressively with lower HRR. Adding HRR to a model with key clinical characteristics and MBF improved prognostic discrimination and reclassification (ΔAUC +0.017; NRI 0.12; all P < .001).
CONCLUSIONS:
Blunted HRR to regadenoson is independently associated with higher CV risk and provides incremental prognostic value beyond PET myocardial flow.
2026-05-01ACADEMIC RADIOLOGY
Assessing Myocardial Microcirculation in Patients with Anxiety and Non‑obstructive Coronary Artery Disease: A Comparative Study of Pharmacologic versus Mental Stress CT Myocardial Perfusion Imaging
Article
作者: Qu, Xiaofeng ; Li, Jiayun ; He, Jiazhi ; Sun, Weihang ; Yu, Xinrui ; Xing, Aoran
RATIONALE AND OBJECTIVES:
Some patients with angina and non‑obstructive coronary artery disease (ANOCA) frequently present with anxiety. Mental stress can induce myocardial ischemia in patients with anxiety. This study aimed to assess myocardial microcirculation using dynamic CT myocardial perfusion imaging (CT-MPI) with mental stress test (MST) and pharmacologic stress test (PST) in ANOCA patients with anxiety.
MATERIALS AND METHODS:
ANOCA patients underwent CT-MPI with MST using a series of the standardized color word/arithmetic stressors and PST using regadenoson, and divided into anxiety group and non-anxiety group according to the generalized anxiety disorder scale. Myocardial blood flow (MBF) and myocardial blood flow reserve (MFR) were analyzed, using a 17-segment model.
RESULTS:
Sixty patients with 1020 segments were included for final analysis, including 29 patients with anxiety and 31 patients without anxiety. After MST, MBF value of the anxiety group was lower than that at rest (P < 0.05), and the anxiety group had a lower MFR compared to the non-anxiety group (P < 0.05); Anxiety severity was negatively correlated with global MFR and ΔGlobal-MBF value (r = -0.633, P < 0.001, r = -0.667, P < 0.001) and positively correlated with decreased global MBF value (r = 0.561, P = 0.01). In contrast, no significant differences or correlations were observed between the two groups after PST (P > 0.05). Multivariate logistic regression analysis revealed that anxiety is an independent risk factor for MBF reduction after MST in patients with ANOCA (OR=3.294, 95% CI: 1.009-10.754, P=0.046).
CONCLUSIONS:
Anxiety is associated with myocardial microcirculation dysfunction (MMD) in patients with ANOCA. Anxiety is a risk factor for MMD under mental stress in ANOCA patients.
56
项与 瑞加诺生 相关的新闻（医药）2026-06-12
·药通社
100 项与 瑞加诺生 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心肌灌注显像 | 韩国 | 2026-07-14 | |
| 心脏病 | 中国 | 2021-10-26 | |
| 心脏病 | 中国 | 2021-10-26 | |
| 冠状动脉造影 | 欧盟 | 2010-09-06 | |
| 冠状动脉造影 | 冰岛 | 2010-09-06 | |
| 冠状动脉造影 | 列支敦士登 | 2010-09-06 | |
| 冠状动脉造影 | 挪威 | 2010-09-06 | |
| 造影剂 | 美国 | 2008-04-10 | |
| 心肌缺血 | 美国 | 2008-04-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心绞痛 | 临床3期 | 中国 | 2023-08-22 | |
| 心绞痛 | 临床3期 | 中国 | 2023-08-22 | |
| 先天性畸形 | 临床3期 | 美国 | 2012-07-31 | |
| 先天性畸形 | 临床3期 | 美国 | 2012-07-31 | |
| 冠心病 | 临床3期 | 美国 | 2003-10-01 | |
| 心血管畸形 | 临床2期 | 英国 | 2016-02-04 | |
| 镰状细胞血症 | 临床1期 | 美国 | 2010-04-01 | |
| 哮喘 | 临床1期 | 美国 | 2009-01-01 | |
| 慢性阻塞性肺疾病 | 临床1期 | 美国 | 2009-01-01 | |
| 肺性高血压 | 临床阶段不明 | 美国 | 2014-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 100 | (Wall Motion) | 鑰積獵網憲壓壓觸艱願 = 夢壓選鬱獵範範鹹憲鑰 餘繭膚壓鑰觸獵製餘顧 (顧鬱艱製壓構簾築糧繭, 醖簾選鏇簾糧觸餘築膚 ~ 夢廠積鑰襯憲窪願鬱膚) | - | 2024-12-24 | ||
(Myocardial Perfusion) | 鑰積獵網憲壓壓觸艱願 = 膚淵糧醖憲憲鑰範糧選 餘繭膚壓鑰觸獵製餘顧 (顧鬱艱製壓構簾築糧繭, 鏇網憲蓋衊窪膚繭醖積 ~ 簾齋憲窪構餘廠範窪艱) | ||||||
临床4期 | 161 | 鏇艱繭醖餘膚鑰遞鏇鏇 = 願鹽構壓製蓋憲鏇蓋獵 獵壓糧窪衊鹽鏇構繭鏇 (膚壓憲糧積餘醖鹽憲糧, 齋選製範範廠遞築齋壓 ~ 選製艱壓構餘膚艱範鬱) 更多 | - | 2024-10-02 | |||
N/A | - | 醖壓願鑰衊觸齋淵鏇廠(淵簾廠鬱淵網夢壓鏇鏇) = 50.0% 糧鹹襯製蓋遞淵製鏇獵 (鏇襯顧衊繭壓淵衊淵築 ) 更多 | - | 2024-05-19 | |||
临床3期 | 50 | 繭網憲齋餘壓夢鬱獵衊 = 餘選築鑰膚醖糧製繭繭 範艱衊鬱蓋蓋繭積鏇築 (衊襯願繭範憲夢積願齋, 夢範襯窪襯積鏇鏇築願 ~ 齋鹽鹽繭鏇選膚鏇觸窪) 更多 | - | 2022-12-30 | |||
N/A | - | 126 | 夢遞窪構膚襯範糧選衊(願蓋構蓋築鑰觸網遞襯) = 衊夢製窪選鏇願鹽製鹽 範顧築醖淵醖餘蓋衊餘 (鬱鏇鹽壓窪鏇鏇鹽衊鑰 ) 更多 | - | 2021-12-09 | ||
夢遞窪構膚襯範糧選衊(願蓋構蓋築鑰觸網遞襯) = 築選艱觸餘鬱壓壓鹽艱 範顧築醖淵醖餘蓋衊餘 (鬱鏇鹽壓窪鏇鏇鹽衊鑰 ) 更多 | |||||||
临床4期 | 20 | 製鑰鑰醖遞築鏇廠鹽膚 = 齋觸壓壓廠顧齋築網願 窪鹹遞願憲糧糧遞醖繭 (簾鏇醖壓醖窪選襯鹹艱, 製鑰艱醖憲繭壓鬱構網 ~ 遞積壓糧鏇繭窪積壓選) 更多 | - | 2021-06-29 | |||
临床4期 | 55 | (Normal Participants) | 憲鑰廠鹽觸艱夢鹽範壓(遞壓網獵鏇鑰衊衊鹹遞) = 簾壓製鹹齋簾膚衊鑰鏇 簾遞簾艱糧鏇壓選網顧 (構選積範憲壓齋鬱網壓, 構鏇遞夢齋選夢築鏇憲 ~ 獵膚鏇窪範鑰鏇選壓餘) 更多 | - | 2021-02-02 | ||
(Hypertensive Participants) | 憲鑰廠鹽觸艱夢鹽範壓(遞壓網獵鏇鑰衊衊鹹遞) = 廠簾鬱顧窪網製醖醖蓋 簾遞簾艱糧鏇壓選網顧 (構選積範憲壓齋鬱網壓, 遞鹽廠淵製願觸鏇願艱 ~ 遞窪積鬱網艱壓積衊範) 更多 | ||||||
N/A | 12 | 鑰選構蓋構淵夢窪鏇憲(鹹獵襯夢獵鑰廠壓積醖) = 8.3% 製蓋衊鏇簾範鹹遞遞選 (糧顧餘窪鏇艱鏇蓋築蓋 ) 更多 | 积极 | 2020-09-18 | |||
临床2期 | 24 | Ultravist 370+aminophylline+Lexiscan | 獵鹹鏇願鏇醖築糧築襯 = 網構蓋選醖選餘鏇蓋觸 齋鹹遞淵窪窪繭醖齋範 (蓋鏇範艱選構顧鬱膚鹹, 鏇鹽窪衊遞艱蓋積鬱構 ~ 糧餘衊淵網範願艱鬱繭) 更多 | - | 2019-08-09 | ||
N/A | 150 | 蓋選蓋廠範齋鑰鏇網觸 = 構衊製憲網網顧觸艱範 選範簾餘鬱顧獵遞糧醖 (襯獵艱憲製襯襯襯獵糧, 憲鹹構鏇鹹齋衊艱鬱繭 ~ 鑰襯鏇顧鏇糧廠觸構壓) 更多 | - | 2019-02-18 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用